GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal

Sonia Brun1, Eloïne Bestion1,2, Eric Raymond1,3

  • 1Genoscience Pharma, Marseille, France.

Autophagy
|November 6, 2021
PubMed

Insights

GNS561, a novel autophagy inhibitor, shows potent antitumor activity against liver cancer by inhibiting PPT1, leading to cell death. Its successful Phase 1b trial offers a promising new therapeutic strategy for hepatocellular carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is the most common primary liver cancer.
  • Existing autophagy inhibitors have not achieved clinical efficacy.
  • GNS561 is a novel autophagy inhibitor with previously observed anticancer activity linked to lysosomal cell death.

Purpose of the Study:

  • To evaluate the efficacy and mechanism of GNS561 in hepatocellular carcinoma.
  • To investigate GNS561's liver tropism and antitumor activity.
  • To explore GNS561's interaction with palmitoyl-protein thioesterase 1 (PPT1) and downstream effects.

Main Methods:

  • In vitro testing against human cancer cell lines.
  • In vivo studies using two hepatocellular carcinoma models.
  • Analysis of lysosomal function, autophagic flux, and cell death pathways.
  • Assessment of GNS561's enzyme target inhibition (PPT1).

Main Results:

  • GNS561 demonstrated high liver tropism and potent antitumor effects in HCC models.
  • GNS561 specifically inhibits PPT1, causing lysosomal zinc accumulation and impaired cathepsin activity.
  • Inhibition of PPT1 by GNS561 blocked autophagic flux, induced lysosomal membrane permeabilization, and activated caspases, leading to cell death.
  • A global Phase 1b clinical trial in liver cancers using GNS561 was successfully completed.

Conclusions:

  • GNS561 is a promising drug candidate for liver cancer treatment.
  • Its mechanism involves specific inhibition of PPT1, leading to lysosomal dysfunction and cancer cell death.
  • GNS561 represents a hopeful therapeutic strategy, supported by successful clinical trial results.